News | July 29, 2025
Piramal Pharma reports Q1 FY26 consolidated loss at Rs. 81.70 Cr
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Sigachi Industries has reported total income of Rs. 132.18 crores during the period ended June 30, 2025
Subscribe To Our Newsletter & Stay Updated
